A Glympse at drug response

Investors poured $22 million into Glympse Bio Inc.’s series A round after the company established plans to apply its sensors to both diagnostics and drug response monitoring.

Polaris Partners and Arch Venture Partners co-led the untranched round, which closed on Oct. 9. Fellow new investors Charles River Ventures, Gilead Sciences Inc. (NASDAQ:GILD), Yonghua Capital and Inevitable Ventures and existing investors GreatPoint Ventures, Heritage Provider Network and Rivas Capital also participated. ...